Stay updated with breaking news from Orphan Receptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […]
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Sunday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $28.00 to $19.00 and set a buy rating on the stock in a research note […]
StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Friday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a […]
StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their price target on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a research […]
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...